FluoroPharma Medical SG&A Expenses 2010-2016 | FPMI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

FluoroPharma Medical sg&a expenses from 2010 to 2016. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

FluoroPharma Medical sg&a expenses from 2010 to 2016. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$195.6B
Stryker (SYK)	$137.3B
Boston Scientific (BSX)	$122.7B
Medtronic (MDT)	$114.6B
EssilorLuxottica (ESLOY)	$108.8B
Haleon (HLN)	$48.7B
Lonza Group Ag (LZAGY)	$46B
ResMed (RMD)	$35.1B
Koninklijke Philips (PHG)	$30.8B
Terumo (TRUMY)	$28.5B
Zimmer Biomet Holdings (ZBH)	$22B
Baxter (BAX)	$19.9B
Insulet (PODD)	$16.3B
Smith & Nephew SNATS (SNN)	$13.6B
Bio-Rad Laboratories (BIO)	$9.2B
Demant (WILYY)	$8.7B
BellRing Brands (BRBR)	$7.9B
Lantheus Holdings (LNTH)	$7.5B
ICU Medical (ICUI)	$4.3B
Haemonetics (HAE)	$4.1B
TG Therapeutics (TGTX)	$3.7B
Neogen (NEOG)	$3.6B
Prestige Consumer Healthcare (PBH)	$3.5B
GN Store Nord (GNNDY)	$3.5B
Perrigo (PRGO)	$3.5B
Envista Holdings (NVST)	$3.4B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Green Thumb Industries (GTBIF)	$2.2B
Maravai LifeSciences Holdings (MRVI)	$2.1B